Literature DB >> 9482170

Activation of the prostaglandin EP4-receptor subtype is highly coupled to inhibition of N-formyl-methionyl-leucyl-phenylalanine-stimulated rat neutrophil aggregation.

H Wise1.   

Abstract

The inhibitory activity of prostaglandin E2 (PGE2) on rat neutrophil aggregation has been studied using the EP4-receptor antagonist AH23848B. While AH23848B antagonized the ability of PGE2 to inhibit neutrophil aggregation stimulated by platelet-activating factor (PAF), AH23848B showed agonist activity when neutrophils were stimulated by N-formyl-methionyl-leucyl-phenylalanine (FMLP). In addition, AH23848B showed weak stimulation of adenylyl cyclase activity and inhibited PGE2-stimulated [3H]cyclic AMP production by rat neutrophils, therefore AH23848B appears to be a partial agonist at EP4-receptors. These results suggest that rat neutrophils possess both inhibitory EP2- and EP4-receptors, and that FMLP-stimulated neutrophil aggregation is more highly coupled to inhibition by EP4-receptor activation than is PAF-stimulated neutrophil aggregation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9482170     DOI: 10.1016/s0952-3278(98)90133-8

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  3 in total

1.  Prostaglandin E(2) increases cyclic AMP and inhibits endothelin-1 production/secretion by guinea-pig tracheal epithelial cells through EP(4) receptors.

Authors:  S Pelletier; J Dubé; A Villeneuve; F Gobeil; Q Yang; B Battistini; G Guillemette; P Sirois
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

2.  Pharmacological characterization of [(3)H]-prostaglandin E(2) binding to the cloned human EP(4) prostanoid receptor.

Authors:  T L Davis; N A Sharif
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

Review 3.  Anti-inflammation therapy by activation of prostaglandin EP4 receptor in cardiovascular and other inflammatory diseases.

Authors:  Eva H C Tang; Peter Libby; Paul M Vanhoutte; Aimin Xu
Journal:  J Cardiovasc Pharmacol       Date:  2012-02       Impact factor: 3.105

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.